The use of high-dose corticosteroids for graft-versus-host disease (GVHD) treatment represents a major risk factor for long-term invasive fungal infections. The aim of this study was to investigate the safety and tolerance of weekly prophylactic administration of once-weekly high-dose (7.5 mg/kg) of liposomal amphotericin B (L-AmB) therapy in 21 adult patients receiving high-dose prednisone (2 mg/kg/day) for acute GVHD therapy after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT). Patients received a median of 4 (range, 1-8) infusions of L-AmB. Seven patients (33%; 95% confidence intervals (CI), 13-53%) discontinued taking the study drug owing to study drug-related adverse events, including elevated serum creatinine (>1.5 times from baseline values; n=5), hypotension and pain (n=1), and violent chest pain and arrhythmia (n=1). The overall frequency of infusion-related reactions was 29% (n=6; 95% CI, 10-48%), but these reactions were always transient and relieved by stopping the infusion. This safety data provide support for an efficacy study of this prophylaxis strategy, because this may help further improving the outcome of RIC or nonmyeloablative allo-SCT.

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.bmt.1705592DOI Listing

Publication Analysis

Top Keywords

liposomal amphotericin
8
allogeneic stem
8
stem cell
8
cell transplantation
8
high-dose
4
high-dose weekly
4
weekly liposomal
4
amphotericin antifungal
4
antifungal prophylaxis
4
prophylaxis reduced-intensity
4

Similar Publications

Hemophagocytic lymphohistiocytosis (HLH) is a rare clinical entity characterized by fever, constitutional symptoms, and hepatosplenomegaly associated with the presence of hemophagocytosis in the bone marrow and other organs. Visceral leishmaniasis (VL) is a severe zoonotic disease hypoendemic in Portugal, particularly in the Alto Douro region. We report the case of a 21-year-old female patient with a recent diagnosis of human immunodeficiency virus (HIV) infection, stage C3, in the context of severe pneumonia, who presented to the emergency department with fever, erythematous rash on the upper limbs and trunk, choluria and jaundice, one week after starting antiretroviral therapy (ART).

View Article and Find Full Text PDF

: In 2022, the World Health Organization highlighted the necessity for the development of new antifungal agents. Polyene antibiotics are characterized by a low risk of drug resistance; however, their use is limited by low solubility and severe side effects. : A series of -alkylated derivatives of amphotericin B and nystatin A as well as their -(2-hydroxyethyl)amides were synthesized.

View Article and Find Full Text PDF

Use of isavuconazole in mucormycosis: a systematic review.

BMC Infect Dis

January 2025

Department of Microbiology Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura Sri Lanka, 50008, Sri Lanka.

Background: Mucormycosis is an opportunistic fungal infection which is associated with poor prognosis. Only a few antifungals are available in the arsenal against mucormycosis. The global guidelines for diagnosing and managing mucormycosis recommend high doses of liposomal amphotericin B (LAmB) as the first-line treatment.

View Article and Find Full Text PDF

is a rapidly emerging fungal pathogen associated with high resistance rates, particularly in healthcare settings. It most commonly affects patients with severe underlying medical conditions and requiring complex medical care. Patients with invasive medical devices tend to be at increased risk for getting and developing infection.

View Article and Find Full Text PDF

spp. are ubiquitous, and people are frequently exposed to their spores in the environment and hospital settings. Despite frequent inhalation of the spores, infection is infrequent in humans, except in immunosuppressed hosts.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!